Epitherix identifies potent and selective multiple chemical scaffolds against colorectal carcinoma

Epitherix, LLC, a privately held company focused on the discovery and development of novel Wnt pathway small molecule inhibitors for epithelial and leukemic cancers, today announced that it has identified multiple chemical scaffolds that are potent and selective against colorectal carcinoma. "We're very encouraged by our in vitro and in vivo data, especially considering the difficulty in drugging this pathway to date," said Dr. Osman Kibar, CEO of Epitherix. "With our clinical candidate nomination expected very soon, we're currently actively exploring strategic partnerships," added Dr. Kibar.

It is estimated that Wnt pathway is implicated in various cancers totaling approximately 600,000 new cases each year in the U.S. alone, with over 90% of colon cancers exhibiting a causative Wnt mutation.